表紙
市場調査レポート

NAL Pharmaceuticals Ltd.:製品パイプライン分析

NAL Pharmaceuticals Ltd. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 315711
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
NAL Pharmaceuticals Ltd.:製品パイプライン分析 NAL Pharmaceuticals Ltd. - Product Pipeline Review - 2016
出版日: 2016年03月22日 ページ情報: 英文 42 Pages
概要

NAL Pharmaceuticals Ltd. は、新たな剤形および薬物送達システムを開発して、同社の送達システムに応用しています。特に中枢神経系疾患、腫瘍、関節炎や急性の疼痛、喫煙、心臓血管およびアレルギー疾患、呼吸器疾患の領域に関した製品を扱っています。

当レポートでは、NAL Pharmaceuticals Ltd.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

NAL Pharmaceuticals Ltd.の基本情報

  • NAL Pharmaceuticals Ltd.の概要
  • 主要情報
  • 企業情報

NAL Pharmaceuticals Ltd.:R&Dの概要

  • 主な治療範囲

NAL Pharmaceuticals Ltd.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

NAL Pharmaceuticals Ltd.:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

NAL Pharmaceuticals Ltd.:開発段階が不明のパイプライン製品

  • 開発段階が不明の製品/併用療法モダリティ

NAL Pharmaceuticals Ltd.:薬剤プロファイル

  • pegfilgrastim
  • diclofenac sodium
  • donepezil hydrochloride
  • donepezil hydrochloride Patch
  • formoterol fumarate patch
  • galantamine
  • indomethacin
  • ketoprofen
  • levocetirizine dihydrochloride
  • montelukast sodium
  • NAL-3216
  • NAL-3221
  • NAL-3223
  • nicotine bitartrate
  • rizatriptan benzoate
  • sildenafil citrate
  • sufentanil
  • tadalafil
  • tulobuterol

NAL Pharmaceuticals Ltd.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

NAL Pharmaceuticals Ltd.:休止中のプロジェクト

NAL Pharmaceuticals Ltd.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07991CDB

Summary

Global Markets Direct's, 'NAL Pharmaceuticals Ltd. - Product Pipeline Review - 2016', provides an overview of the NAL Pharmaceuticals Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by NAL Pharmaceuticals Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of NAL Pharmaceuticals Ltd.
  • The report provides overview of NAL Pharmaceuticals Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses NAL Pharmaceuticals Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features NAL Pharmaceuticals Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate NAL Pharmaceuticals Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for NAL Pharmaceuticals Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding NAL Pharmaceuticals Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • NAL Pharmaceuticals Ltd. Snapshot
    • NAL Pharmaceuticals Ltd. Overview
    • Key Information
    • Key Facts
  • NAL Pharmaceuticals Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • NAL Pharmaceuticals Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • NAL Pharmaceuticals Ltd. - Pipeline Products Glance
    • NAL Pharmaceuticals Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • NAL Pharmaceuticals Ltd. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • NAL Pharmaceuticals Ltd. - Drug Profiles
    • pegfilgrastim
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • montelukast sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diclofenac sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • donepezil hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • donepezil hydrochloride Patch
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • formoterol fumarate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • galantamine hydrobromide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • indomethacin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ketoprofen
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • levocetirizine dihydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NAL-3216
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NAL-3221
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NAL-3223
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nicotine bitartrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rizatriptan benzoate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sildenafil citrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sufentanil citrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tadalafil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tulobuterol
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • NAL Pharmaceuticals Ltd. - Pipeline Analysis
  • NAL Pharmaceuticals Ltd. - Pipeline Products by Target
  • NAL Pharmaceuticals Ltd. - Pipeline Products by Route of Administration
  • NAL Pharmaceuticals Ltd. - Pipeline Products by Molecule Type
  • NAL Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action
  • NAL Pharmaceuticals Ltd. - Dormant Projects
  • NAL Pharmaceuticals Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • NAL Pharmaceuticals Ltd., Key Information
  • NAL Pharmaceuticals Ltd., Key Facts
  • NAL Pharmaceuticals Ltd. - Pipeline by Indication, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2016
  • NAL Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2016
  • NAL Pharmaceuticals Ltd. - Preclinical, 2016
  • NAL Pharmaceuticals Ltd. - Discovery, 2016
  • NAL Pharmaceuticals Ltd. - Unknown, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline by Target, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action, 2016
  • NAL Pharmaceuticals Ltd. - Dormant Developmental Projects,2016

List of Figures

  • NAL Pharmaceuticals Ltd. - Pipeline by Top 10 Indication, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2016
  • NAL Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline by Top 10 Target, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline by Top 10 Route of Administration, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top